Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16660665 | 0.84 | BRD4 (0.69) | BRD4MAPK8MAPK14CREBBP | |
| SCHEMBL16657994 | 0.82 | BRD4 (0.78) | BRD4MAPK8MAPK14CREBBP | |
| SCHEMBL16657969 | 0.81 | BRD4 (1.00) | BRD4MAPK8MAPK14CREBBP | |
| SCHEMBL16651449 | 0.78 | BRD4 (0.78) | BRD4MAPK8MAPK14CREBBP | |
| SCHEMBL16651728 | 0.78 | BRD4 (0.71) | BRD4MAPK8MAPK14 | |
| SCHEMBL17703370 | 0.78 | BRD4 (0.59) | BRD4CREBBP | |
| SCHEMBL16660678 | 0.77 | BRD4 (0.37) | BRD4 | |
| SCHEMBL16660694 | 0.76 | BRD4 (0.37) | BRD4MAPK8MAPK14 | |
| SCHEMBL25043182 | 0.68 | BRD4 (0.74) | BRD4MAPK8MAPK14CREBBP | |
| SCHEMBL25042148 | 0.68 | BRD4 (0.60) | BRD4MAPK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK8 1913/4885MAPK14 2056/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK8 1913/4885MAPK14 2056/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK8 1913/4885MAPK14 2056/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK8 1913/4885MAPK14 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.